Soquelitinib

N/A

Report date: 2026/04/09 20:00:21
NME

Base Information

Drug NameSoquelitinib
Drug Alias NameCPI 818CPI-818CP 000596CPI 000818CPI 596
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase ITK/TSK inhibitors
TargetsTyrosine-protein kinase ITK/TSK
Therapy Area/IndicationsSolid tumoursAngioimmunoblastic T-cell LymphomaEczema +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[5] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesCorvus Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAngel Pharmaceuticals Co LtdPatheon Development Services IncCorvus Pharmaceuticals Inc +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursAngioimmunoblastic T-cell LymphomaEczema +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksKEGG